Group 1 - The newly approved drug, Lemborexant (brand name: Dazavt), is a novel insomnia therapy that works by inhibiting the wake-promoting effects of orexin, differing from traditional medications [1] - Lemborexant is a dual orexin receptor antagonist that targets both OX1R and OX2R receptors, allowing for precise regulation of the orexin system [1] - The drug has been approved for the treatment of adult insomnia, particularly for those with difficulties in falling asleep and/or maintaining sleep [1] Group 2 - Professor Chen Jun from Shanghai Mental Health Center highlighted that the mechanism of this new drug represents an innovation compared to traditional benzodiazepines, which have safety concerns [3] - Traditional benzodiazepines can lead to addiction, tolerance, and various side effects, including cognitive impairment and dependence [3] - Lemborexant has been included in the "Guidelines for the Diagnosis and Treatment of Insomnia in Adults (2023 Edition)" as an IA-level recommended drug [3] Group 3 - The first step in standardized treatment for insomnia is not medication, but rather the adjustment of healthy sleep habits and psychological therapy, with medication considered only if these methods are ineffective [4]